

**Title:** Magnitude of Potential Biases in COVID-19 Vaccine Effectiveness Studies due to Differential Healthcare seeking following Home Testing: Implications for Test Negative Design Studies

**Authors:** Saba A. Qasmieh<sup>a,b</sup>, Jill M. Ferdinands<sup>c</sup>, Jessie R. Chung<sup>c</sup>, Ryan E. Wiegand<sup>d</sup>, Brendan Flannery<sup>c</sup>, Madhura S. Rane<sup>a</sup>, Denis Nash<sup>a,b</sup>

<sup>a</sup>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY 10027, USA

<sup>b</sup>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY 10027, USA

<sup>c</sup>Influenza Division, U.S Centers for Disease Control and Prevention, Atlanta, GA 30333, USA

<sup>d</sup>Coronavirus and Other Respiratory Viruses Division, U.S Centers for Disease Control and Prevention, Atlanta, GA 30333, USA

#### **Funding and Conflicts of interest:**

Denis Nash reports a past relationship with Gilead Sciences Inc that includes consulting or advisory. Denis Nash reports a past relationship with AbbVie Inc that includes consulting or advisory. The City University of New York (CUNY) School of Public Health received research support from Pfizer during the conduct of this study that was paid directly to CUNY, with Dr. Nash serving as the Principal Investigator.

Funding for this project is provided by The National Institute of Allergy and Infectious Diseases (NIAID), award number UH3AI133675 (MPIs: D Nash and C Grov), Pfizer Inc., the CUNY Institute for Implementation Science in Population Health ([cunyisph.org](http://cunyisph.org)), and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy. The funders played no role in the production of this manuscript nor necessarily endorse the findings.

#### **Disclaimer:**

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

## Abstract

The test-negative design (TND) is widely used to estimate COVID-19 vaccine effectiveness (VE). Biased estimates of VE may result from effects of at-home SARS-CoV-2 rapid diagnostic test (RDT) results on decisions to seek healthcare. To investigate magnitude of potential bias, we constructed decision trees with input probabilities obtained from longitudinal surveys of U.S. adults between March 2022 – October 2023. Prevalence of at-home RDT use and healthcare seeking following a positive or negative RDT result was estimated by participant vaccination status and socio-demographic characteristics. At true *VE* values ranging from 5% to 95%, we defined bias as the difference between the observed and true *VE*. Among 1,918 symptomatic adults, prevalence of at-home RDT use was higher among vaccinated (37%) versus unvaccinated (22%) participants. At-home RDT use was associated with seeking care, and participants reporting positive RDT were more likely than those reporting negative RDT to have sought care when ill. In primary analyses, we observed downward bias in VE estimates that increased in magnitude when true *VE* was low. Variations in proportions of vaccination, at-home RDT use and healthcare seeking by socio-demographic characteristics may impact VE estimates. Further evaluation of potential impact of at-home RDT use on VE estimates is warranted.


## Introduction

The effectiveness of COVID-19 vaccines in protecting against severe outcomes has been largely informed by retrospective observational studies, such as test-negative design (TND) case-control studies<sup>1-3</sup>. Studies that use the TND approach for estimating vaccine effectiveness (VE) aim to reduce bias associated with differential healthcare seeking between vaccinated and unvaccinated persons<sup>4,5</sup>. In such studies, COVID-19 vaccination status is compared between symptomatic patients who test positive for SARS-CoV-2 infection at healthcare facilities, and patients with similar symptoms who test negative for SARS-CoV-2. The design assumes that healthcare seeking is independent of infection status among vaccinated and unvaccinated individuals. When case status is assigned based on testing performed for clinical decision making, uncontrolled factors that influence healthcare seeking may introduce bias if clinical testing varies by patient vaccination and infection status<sup>5-7</sup>. With widespread availability of rapid diagnostic tests for SARS-CoV-2 infection, the effect of self-testing prior to seeking care has the potential to introduce selection bias in TND studies.

The development and approval of rapid SARS-CoV-2 diagnostic tests for home use served a critical public health function for early diagnosis of COVID-19 to mitigate spread of infection and helped alleviate burden on SARS-CoV-2 testing facilities during pandemic waves or increased COVID-19 activity<sup>8,9</sup>. To assess the potential for bias in TND studies of COVID-19 VE among individuals seeking care for COVID-19-like illness, we constructed a decision tree model that simulates a TND case-control study of VE. Informed by a directed acyclic graph (DAG), we explored potential bias in observed VE estimates. We used a simulation model and observational survey data on prevalence of COVID-19 vaccination, use of at-home SARS-CoV-2 rapid diagnostic tests (RDT) and healthcare seeking for COVID-19-like illness among adults  $\geq 18$  years participating in a diverse U.S. cohort study between March 2022 and October 2023 when rapid at-home COVID-19 test kits were widely available.

## Methods

*Theoretical Basis:* Figure 1 presents a DAG depicting potential causal relationships in a TND study of COVID-19 VE. In the assumed causal relationship between COVID-19 vaccination ( $V_{cov}$ ) and COVID-19-like illness ( $I_{cov}$ ), the graph illustrates other potential determinants of  $V_{cov}$  and  $I_{cov}$  such as use of at-home RDT, home test result (positive or negative), and healthcare seeking behavior ( $HS$ ). A TND study aims to reduce bias associated with healthcare seeking behavior  $HS$  by restricting the study population to patients who seek care and receive a diagnostic SARS-CoV-2 test ( $T_{cov}$ ). The relationship between RDT,  $V_{cov}$ , and  $HS$  creates a back-door path between  $V_{cov}$  and  $I_{cov}$ . Selection bias would result if RDT and receiving a diagnostic SARS-CoV-2 test with a provider differ by COVID-19 vaccination status, such that vaccinated and unvaccinated patients have different probabilities of selection  $T_{cov}(S)$  into TND following their at-home RDT result. Since the uptake of SARS-CoV-2 home testing has been observed to increase during surges<sup>10</sup> with differential use among individuals across socio-demographic characteristics<sup>10</sup>, simulations based on survey data may be used to assess the magnitude of potential bias in COVID-19 VE estimates.



**Figure 1:** Directed acyclic graph (DAG) depicting causal relationships between at-home SARS-CoV-2 rapid diagnostic testing (*RDT*), home test result (*RDT result* [positive or negative]), COVID-19 vaccination status ( $V_{cov}$ ), SARS-CoV-2 infection ( $Inf_{SARS-CoV-2}$ ), COVID-19-like illness ( $I_{cov}$ ), healthcare seeking behavior (*HS*), and COVID-19 testing by a healthcare provider ( $T_{cov}(S)$ ). The box around  $T_{cov}(S)$  represents selection into the TND study and determination of COVID-19 case status. The DAG assumes all patients presenting with COVID-19-like illness symptoms are systematically tested for COVID-19 using molecular testing with high sensitivity and specificity. Other potential confounding factors including patient characteristics associated with  $V_{cov}$ , *HS*, and  $I_{cov}$  are not depicted in this graph.

**Decision Tree Structure:** We constructed a decision tree to simulate numbers of persons vaccinated and unvaccinated against COVID-19 experiencing acute respiratory illness (ARI) due to COVID-19 or non-COVID-19 illness who sought care and were subsequently included in the TND study as test-positive cases and test-negative control patients (Supplemental Figure 1). Individuals reporting ARI symptoms who were vaccinated are denoted by the probability  $V_{cov}$ , or unvaccinated with probability  $1-V_{cov}$ . Probabilities of vaccinated and unvaccinated individuals taking at-home SARS-CoV-2 RDT for ARI symptoms are denoted by  $RDT_v$  and  $RDT_u$ , respectively. Probabilities of vaccinated and unvaccinated individuals seeking healthcare for ARI symptoms are denoted by  $HS_v$  and  $HS_u$ , respectively.  $HS_vRDT+$ ,  $HS_vRDT-$ ,  $HS_uRDT+$ , and  $HS_uRDT-$  denote probabilities of vaccinated and unvaccinated individuals with ARI seeking care following their at-home rapid diagnostic test result (positive or negative) (Table 1).

As the effect of interest was the probability of seeking care for ARI symptoms based on at-home RDT test result rather than test accuracy among vaccinated and unvaccinated individuals, we assumed perfect concordance between the at-home RDT and provider-based testing that determine case status. All persons seeking care were assumed to be tested for SARS-CoV-2 infection and included in the TND study as SARS-CoV-2 test-positive cases or test-negative controls.

**Decision Tree Input Values:** We varied the values of factors that could affect observed VE ( $\widehat{VE}$ ), including COVID-19 vaccination uptake, probability of at-home RDT use that was stratified by vaccination status, and likelihood of seeking healthcare for ARI symptoms following home testing, also stratified by vaccination status and at-home RDT result. Each of these variables was defined by

a probability distribution—a summary of the possible values of the variable—based on results from a national survey as described below. We used a beta distribution to represent each probability entered into the decision tree model. A beta distribution is typically used to represent probabilities because it is a flexible, continuous distribution bounded by values of zero and one<sup>11</sup>. Each beta distribution is summarized by two shape parameters: when representing the probability of a binary event, these parameters represent the number of positive responses observed and the number of negative responses observed (Supplemental Table 1). We obtained empirical values of these parameters directly from the CHASING COVID Cohort,<sup>12</sup> a geographically and socio-demographically diverse longitudinal cohort study of approximately 6,740 adults residing in the U.S. and its territories. Cohort participants were recruited via social media or by referral and received electronic survey questionnaires approximately every three months beginning in March 2020. The surveys captured information on SARS-CoV-2 infections, COVID-19 testing behaviors, test results, vaccination status and healthcare seeking among other outcomes. Study methods and survey instruments are publicly available<sup>12</sup>. All CHASING COVID Cohort participants provided written informed consent before cohort enrollment. The IRB of the City University of New York gave ethical approval for the study procedures and protocols.

Probabilities were calculated using responses from participants who completed a survey between March 2022 – October 2023 and reported experiencing new ARI symptoms (cough, runny nose, sore throat, shortness of breath) since the previous survey. For participants with multiple episodes, only the first reported ARI was included. Vaccination status was defined based on reported receipt of the latest FDA-approved COVID-19 booster dose at the time of survey administration. For participants who completed the survey questionnaire administered between March 2022 and September 2022, vaccination was defined as those who received the mRNA monovalent COVID-19 booster vaccine (fourth COVID-19 dose). From September 2022 through September 2023, vaccination status was based as those who received the bivalent mRNA COVID-19 booster vaccine, and the updated 2023-2024 COVID-19 booster vaccine for participants completing the survey in October 2023. Unvaccinated participants were those who did not receive the most recent booster dose at or before prior survey's fielding day. Probability of home testing was calculated as the proportion of participants reporting an ARI episode who took an at-home RDT because of acute symptoms. Participants who reported taking an at-home RDT during the time period for other reasons (e.g., required COVID-19 screening in the workplace) were classified as non-home testers. COVID-19 case status was based on a participant's self-reported SARS-CoV-2 positive or negative viral diagnostic test for their ARI episode. Probability of seeking care for ARI was estimated from participants who reported seeing or calling a physician or health care professional for their ARI symptoms. Questions used to calculate each probability are shown in Supplemental Table 2.

In addition to the base model, we varied the decision tree parameters to reflect alternate scenarios by the following socio-demographic characteristics: race/ethnicity (non-Hispanic White, non-Hispanic Black, and Hispanic), education attainment (below, at or above high school attainment), and annual household income level (<\$50,000, \$50,000 – \$100,000, and >\$100,000).

**Table 1:** Parameters of factors that influence COVID-19 vaccine effectiveness estimation in symptomatic individuals sampled in test-negative design case-control studies.

Parameter notation	Description
	Vaccination
$V_{cov}$	Probability of receiving recent COVID-19 booster
	Home testing
$RDT$	Probability of home testing overall
$RDT_v$	Probability of home testing among vaccinated
$RDT_u$	Probability of home testing among unvaccinated
	Healthcare seeking among vaccinated
$HS_vRDT+$	Probability of seeking care among vaccinated given positive test
$HS_vRDT-$	Probability of seeking care among vaccinated given negative test
$HS_v$	Probability of seeking care among vaccinated given no home testing
	Healthcare seeking among unvaccinated
$HS_uRDT+$	Probability of seeking care among unvaccinated given positive test
$HS_uRDT-$	Probability of seeking care among unvaccinated given negative test
$HS_u$	Probability of seeking care among unvaccinated given no home testing

*Simulations:* Using Monte Carlo methods<sup>11</sup>, we simulated the total number of COVID-19 cases and controls, number of vaccinated cases and controls, and ratio of vaccinated to unvaccinated cases and controls based on the input probability distributions. The observed mean VE value ( $\widehat{VE}$ , expressed as percent) was calculated as  $(1 - \text{Odds Ratio [OR]}) \times 100$  comparing vaccination odds among test-positive cases versus test-negative controls. Credible intervals were defined by the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the distribution of  $\widehat{VE}$ . Percent bias was defined as the absolute difference between true VE and  $\widehat{VE}$ . Simulations were run at six values of true VE (5, 10, 20, 40, 60, 80, 95) to assess magnitude of bias across a plausible range of COVID-19 VE. We varied values across the range of their distributions to examine the sensitivity of the results to changes in parameter values. Tornado plots were used to examine the sensitivity  $\widehat{VE}$  by varying values of each parameter by +/- one standard deviation (SD) from the mean. We show in descending rank order the most to least influential parameters that effect estimated  $\widehat{VE}$ . At true VE set at high (60%) and low (20%) values, the input value of the most influential parameter was varied by +/- 10% from the mean to examine the influence on  $\widehat{VE}$ . We further assessed magnitude of bias across socio-demographic characteristics with true VE set at 20% and 60%. Finally, we performed two sensitivity analyses at a true VE of 20%: 1) simulations were conducted with an at-home RDT sensitivity of 64% and 100% specificity, based on a review of RDT sensitivity<sup>13</sup>; and 2) adjusting proportions seeking care after a positive test if the at-home RDT was negative. For the second sensitivity analysis, we used responses from one survey round among symptomatic participants who reported taking an at-home

RDT, seeking care and testing positive with a provider (Supplementary Table 2). Of these, 24% reported testing positive after seeking care. VE simulations were conducted using @RISKv8.6 (Palisade Corp, Ithaca, NY).

## Results

Input probabilities for the base decision tree model were obtained by summarizing responses from 1,918 participants with ARI symptoms between March 2022 – October 2023 (Table 2). Overall, 70% of participants in the study sample during that period reported receiving recent COVID-19 vaccination. A total of 33% of participants with ARI symptoms reported use of an at-home RDT for their illness: 37% of vaccinated and 22% of unvaccinated participants. Healthcare seeking for ARI was associated with COVID-19 vaccination and at-home RDT use. Among vaccinated participants, 47% of those reporting a positive at-home test, 37% of those reporting a negative test, and 23% of those who did not take an at-home RDT sought care for their ARI symptoms. Among unvaccinated participants, 44% of those reporting a positive test, 24% of those reporting negative test, and 23% of those who did not use an at-home RDT sought care for their ARI symptoms (Table 2).

**Table 2:** Decision tree probability values based on survey responses among participants reporting acute respiratory illness symptoms during March 2022 - October 2023 (N = 1,918)


Parameter notation	Definitions from survey	Parameter1: Positive Responses	Parameter 2: Negative Responses	Value	SD
<b>Vaccination</b>					
$V_{cov}$	Proportion of COVID-19 booster vaccination among adults reporting ARI since last survey	1335	583	0.70	0.01
<b>Home testing</b>					
$RDT$	Proportion of home test use among adults with ARI symptoms	623	1295	0.33	0.01
$RDT_v$	Proportion of home test use among vaccinated adults with ARI symptoms	497	838	0.37	0.01
$RDT_u$	Proportion of home test use among unvaccinated adults with ARI symptoms	126	457	0.22	0.02
<b>Healthcare seeking among vaccinated</b>					
$HS_vRDT+$	Proportion of vaccinated adults with ARI who sought care after positive home test	86	98	0.47	0.04

<b><i>HS<sub>v</sub>RDT-</i></b>	Proportion of vaccinated adults with ARI who sought care after negative home test	94	219	0.30	0.03
<b><i>HS<sub>v</sub></i></b>	Proportion of vaccinated adults with ARI who sought care after no home test	192	646	0.23	0.01
<b>Healthcare seeking among unvaccinated</b>					
<b><i>HS<sub>u</sub>RDT+</i></b>	Proportion of unvaccinated adults with ARI who sought care after positive home test	28	35	0.44	0.06
<b><i>HS<sub>u</sub>RDT-</i></b>	Proportion of unvaccinated adults with ARI who sought care after negative home test	15	48	0.24	0.05
<b><i>HS<sub>u</sub></i></b>	Proportion of unvaccinated adults with ARI who sought care after no home test	105	352	0.23	0.02

*Abbreviations: ARI: Acute respiratory illness; RDT: at-home rapid diagnostic test; HS: healthcare seeking; SD: standard deviation. Standard deviation for variance of the distribution was calculated using the formula  $\sigma = \mu(1 - \mu)/(T + 1)$ ; where  $\mu$  (mean) =  $\alpha/\alpha + \beta$ ;  $T$  (precision) =  $\alpha + \beta$ ; and  $\alpha, \beta$ , denote parameters 1 and 2.*



In the base model with 95% credible intervals obtained from Monte Carlo simulations,  $\widehat{VE}$  underestimated true  $VE$  in all model iterations with increasing bias at lower levels of true  $VE$ . The decision tree model simulations with input values from the survey data indicated a percent bias of 5-percentage point downward difference between  $\widehat{VE}$  and true  $VE$  value at values from 5% to 95%. This downward bias was minimal at true  $VE$  above 40% and approached 5-percentage point difference at true  $VE$  below 40%. At true  $VE$  of 20%,  $\widehat{VE}$  was 16.3%. At true  $VE$  of 60%,  $\widehat{VE}$  was 58.1% (Figure 2).



True VE (%)	5	10	20	40	60	80	95
Percent Bias	-4.4	-4.2	-3.7	-2.8	-1.9	-0.9	-0.2


**Figure 2:** Graph showing simulated observed vaccine effectiveness ( $\widehat{VE}$ ) (blue line) against ranging true  $VE$  values (5, 10, 20, 40, 60, 80, 95) in the base model. The gray shaded area represents the 95% credible intervals. The dotted gray line is the line of identity ( $\widehat{VE} = VE$ ). Percent bias is the absolute difference between  $\widehat{VE}$  and true  $VE$ .

The magnitude but not the rank order of influence of a parameter on estimated VE varied by true VE values. Probability of healthcare seeking among unvaccinated adults reporting negative at-home RDT,  $HS_uRDT-$ , and the probability of at-home RDT use among vaccinated adults,  $RDT_v$ , were the most and least influential parameters on VE estimates, respectively (Figure 3). At a true VE of 20%, one SD higher in the probability of healthcare seeking among unvaccinated adults who tested positive resulted in a 4-percentage point increase in  $\widehat{VE}$  (Figure 3a) and 2-percentage point increase in  $\widehat{VE}$  when true VE was 60% (Figure 3b).

To examine the effect of varying the most influential variable on downward bias in  $\widehat{VE}$ , probability of seeking care among unvaccinated adults with ARI following negative at-home RDT, we raised the input probability for  $HS_uRDT-$  by 10% to 0.34. When true VE was below 10%, estimated  $\widehat{VE}$  was negative. At true VE of 20% or 60%,  $\widehat{VE}$  was 8.5% and 77.1%, respectively. Alternatively, an input probability of 0.14 for  $HS_uRDT-$ , resulted in  $\widehat{VE}$  of 24.1% at true VE of 20%, and  $\widehat{VE}$  of 62.1% at true VE of 60% (Supplemental Table 3).

In sensitivity analyses with true VE of 20%, a lower at-home RDT sensitivity resulted in a  $\widehat{VE}$  of 17.6%. A higher proportion of persons seeking care following a negative at-home RDT resulted in a  $\widehat{VE}$  of 17.5% when true VE was 20%.

Finally, we examined the effect on  $\widehat{VE}$  by replacing input probabilities from the entire survey sample with probabilities based on socio-demographic characteristics of survey participants. Overall vaccination uptake  $V_{cov}$  and probability of at-home RDT use varied by socio-demographic characteristics (Table 3). However, at-home RDT use among vaccinated participants,  $RDT_v$ , was consistently higher than among unvaccinated participants,  $RDT_u$ . Differences in the magnitude and direction of bias in  $\widehat{VE}$  illustrated the influence of multiple factors. Among participants reporting annual household income  $> \$100,000$ , a high  $V_{cov}$  (0.87) and at-home RDT use (0.42), combined with a lower probability of healthcare seeking following a negative RDT among vaccinated,  $HS_vRDT-$  (0.24), compared to unvaccinated,  $HS_uRDT-$  (0.40), resulted in  $\widehat{VE}$  of -22% at true VE of 20% and 39% at true VE of 60%. In contrast, among non-Hispanic Black participants and those reporting annual household income between \$50,000-\$100,000, higher probability of healthcare seeking following a positive test among unvaccinated,  $HS_uRDT+$ , versus vaccinated participants,  $HS_vRDT+$ , resulted in a substantially overestimated  $\widehat{VE}$ .



**Figure 3:** Tornado plot showing the effects of varying parameters on  $\widehat{VE}$ . Plots show in rank order the most to least (top-down y-axis) influential parameters that affect estimated  $\widehat{VE}$ . Figure 3a (top plot) shows the effect of one standard deviation increase in each parameter on change in  $\widehat{VE}$  when true VE is 20%. Figure 3b (bottom plot) shows effects of one standard deviation increase in each parameter on change in  $\widehat{VE}$  when true VE is 60%. These values can be interpreted as the percentage point change for each one standard deviation increase in the respective model input.

**Table 3:** Decision tree input values for factors associated with COVID-19 vaccine effectiveness estimation across select socio-demographic characteristics, March 2022 – October 2023, (N=1,918)

<i>Notation</i>	Definitions from survey	Hispanic	NH Black	NH White	< High school	≥High school	<\$50,000	\$50,000 - \$100,000	>\$100,000
		n	n	n	n	n	n	n	n
		289	163	1259	223	1687	765	518	512
<b>Vaccination</b>									
<i>V<sub>cov</sub></i>	Proportion of COVID-19 booster vaccination among adults reporting ARI since last survey	0.58	0.45	0.76	0.35	0.74	0.57	0.75	0.87
<b>Home testing</b>									
<i>RDT</i>	Proportion of home test use among adults with ARI symptoms	0.26	0.18	0.35	0.21	0.34	0.27	0.33	0.42
<i>RDT<sub>v</sub></i>	Proportion of home test use among vaccinated adults with ARI symptoms	0.29	0.27	0.39	0.25	0.38	0.34	0.36	0.44
<i>RDT<sub>u</sub></i>	Proportion of home test use among unvaccinated adults with ARI symptoms	0.23	0.10	0.26	0.19	0.23	0.19	0.23	0.27
<b>Healthcare seeking among vaccinated</b>									
<i>HS<sub>v</sub>RDT+</i>	Proportion of vaccinated adults with ARI who sought care after positive home test	0.58	0.40	0.46	0.50	0.47	0.56	0.40	0.48
<i>HS<sub>v</sub>RDT-</i>	Proportion of vaccinated adults with ARI who sought care after negative home test	0.41	0.53	0.27	0.25	0.30	0.32	0.27	0.24
<i>HS<sub>v</sub></i>	Proportion of vaccinated adults with ARI who sought care after no home test	0.23	0.26	0.23	0.29	0.23	0.27	0.22	0.19
<b>Healthcare seeking among unvaccinated</b>									
<i>HS<sub>u</sub>RDT+</i>	Proportion of unvaccinated adults with ARI who sought care after positive home test	0.25	0.75	0.53	0.29	0.49	0.41	0.56	0.39

<b><i>HS<sub>u</sub>RDT-</i></b>	Proportion of unvaccinated adults with ARI who sought care after negative home test	0.25	0.20	0.26	0.8	0.29	0.31	0.15	0.40
<b><i>HS<sub>u</sub></i></b>	Proportion of unvaccinated adults with ARI who sought care after no home test	0.20	0.21	0.24	0.28	0.21	0.25	0.21	0.13
<b>True VE</b>		<b>Observed VE (<math>\widehat{VE}</math>) (%)</b>							
<b>20%</b>		6%	43%	19%	16%	17%	4%	35%	-22%
<b>60%</b>		53%	72%	60%	58%	58%	52%	68%	39%
<i>Abbreviations: ARI: acute respiratory illness; RDT: at-home rapid diagnostic test; VE, COVID-19 vaccine effectiveness; HS: healthcare seeking.</i>									

## Discussion

Our study presents a theoretical model to assess potential bias in estimates of COVID-19 vaccine effectiveness using TND case-control studies when at-home RDT use influences healthcare seeking for COVID-19-like illness. Using probabilities for key input parameters based on a diverse group of survey respondents in a longitudinal cohort, observed COVID-19  $\widehat{VE}$  underestimated true  $VE$  by less than 5 percentage points across a range of true  $VE$  values. Our observed bias was within confidence bounds of many COVID-19 vaccine effectiveness estimates<sup>14</sup>. However, by substituting probabilities observed in specific socio-demographic groups of participants, we found potentially large biases in either direction. Differences in healthcare seeking among vaccinated versus unvaccinated persons following home testing influenced the magnitude and direction of bias. In contrast, there is less potential for bias from variation in healthcare seeking behavior among persons who did not home test, based on probabilities derived from survey data.

Importantly, based on probabilities of COVID-19 vaccination, home testing and healthcare seeking observed among survey respondents with annual household incomes >\$100,000, apparent  $\widehat{VE}$  estimates were negative at low values of vaccine effectiveness. While we observed minimal bias when vaccination was >80% effective, we observed downward bias resulting in null or negative findings at true  $VE$  <40%. Findings of null or negative  $VE$  findings may contribute to lack of public confidence that vaccine provides benefit, potentially depressing vaccine demand and uptake<sup>15,16</sup>. Among respondents with household incomes >\$100,000 and vaccination uptake >70%, underestimation of  $\widehat{VE}$  was associated with higher percentages reporting at-home RDT for illness and seeking care following positive RDT results. Among non-Hispanic Black participants, overestimation of  $\widehat{VE}$  was associated with higher probability of healthcare seeking among unvaccinated cases. Knowledge of at-home RDT use among populations seeking care is important when interpreting apparent differences in vaccine effectiveness by socio-demographic characteristics of patients.

In simulations, we observed a potential for selection bias in TND studies when home testing influenced symptom-driven healthcare seeking by vaccination status among cases and controls. In our base model, the probability of healthcare seeking following a test-positive result was higher among vaccinated than unvaccinated persons, and lower among vaccinated test-negative persons, favoring the selection of vaccinated cases and resulting in underestimated vaccine effectiveness. When vaccination is highly protective, vaccinated persons would be less likely to have COVID-19 and test positive by RDT if they took an at-home test, resulting in less bias even when healthcare seeking is influenced by at-home RDT use. In simulations, lower RDT sensitivity also reduced  $VE$  bias because participants were less likely to seek care after a negative test.

The observed higher probability of healthcare seeking among vaccinated persons using at-home SARS-CoV-2 RDT may be explained by general health protective behaviors among those who received the COVID-19 vaccine<sup>5</sup>. At-home SARS-CoV-2 RDT use has been shown to be associated with vaccination status<sup>17</sup> and higher SES<sup>10</sup>. In addition, healthcare access and use of antivirals such as nirmatrelvir/ritonavir (Paxlovid™) have been shown to have disparities across race and ethnicity<sup>18</sup>.


Our assessment of bias based on differential probabilities across socio-demographic characteristics highlighted the impact of differences in at-home RDT use and healthcare seeking on VE estimation from TND studies conducted in different populations. Care settings are associated with patient socioeconomic characteristics<sup>19,20</sup>. For example, insured patients who are more likely to be vaccinated and test at home may be overrepresented in outpatient settings, whereas uninsured and under-insured patients may make up a larger proportion of hospitalized patients<sup>21</sup> highlighting the potential implications on TND studies and VE estimation.

Testing using over the counter at-home RDTs for COVID-19, influenza and respiratory syncytial virus is likely to become more widely available. Monitoring at-home RDT uptake is needed to evaluate potential influence on vaccine effectiveness studies for these vaccine preventable respiratory diseases<sup>22</sup>. Previous studies have demonstrated the potential underestimation of COVID-19 incidence when results of at-home SARS-CoV-2 RDT were not included in case counts<sup>23</sup>. In 2021, almost half of CHASING COVID cohort participants who reported use of at-home RDT for COVID-19-like symptoms had used at-home tests exclusively and did not receive testing from a provider. Significant underestimation of COVID-19 prevalence was also observed in comparison to estimates from population-representative adults in NYC and in the U.S.<sup>24,25</sup>. High uptake of at-home RDT can not only underestimate infection prevalence, but can lead to potential bias in VE studies and impact communication of the benefits of the vaccination<sup>22</sup>.

Our study had several limitations. First, we used probabilities for input parameters from a non-representative cohort of survey respondents. Second, survey data were collected over a 20-month period when home tests were widely available through federal and local governments<sup>26,27</sup>. We did not account for temporal trends in healthcare seeking and use of at-home SARS-CoV-2 RDT. Third, we assumed the at-home SARS-CoV-2 RDT result was the same as provider-test for TND case classification. Among a subset of participants asked specifically about the result for at-home RDT, magnitude and direction of bias were similar to the base model assuming that a proportion of non-COVID-19 patients had a false positive RDT that influenced their decision to seek healthcare. Fourth, in the main analysis we assumed there were no differences in at-home RDT sensitivity and specificity by vaccination status or prior infection. The use of less sensitive at-home RDTs tended to reduce the magnitude but not change the direction of bias. Finally, COVID-19 vaccination, testing and healthcare behaviors were based on self-report which may not reflect true behaviors.

This study highlights the potential impact of at-home SARS-CoV-2 RDT use on COVID-19 vaccine effectiveness estimation. Population-based surveys are needed to monitor uptake of home testing<sup>28,29</sup>; other sources include electronic medical records or manufacturer supply chain information<sup>30</sup>. Information about healthcare seeking and COVID-19 home testing is needed to evaluate potential for biased estimates from observational studies using TND.








**Supplemental Figure 1:** Decision tree depicting factors associated with COVID-19 vaccine effectiveness estimation. Chance nodes are shown by circles, which denote outcomes that may occur by chance at each point in the tree with likelihood of occurrence given by the probability shown under each branch ( $V_{cov}$ ,  $RDT_v$ ,  $RDT_u$ ,  $HS_v$ ,  $HS_u$ ,  $HS_vRDT+$ ,  $HS_vRDT-$ ,  $HS_uRDT+$ , and  $HS_uRDT-$ ). Terminal nodes (triangles) represent the observed study outcomes of cases and controls based on healthcare provider SARS-CoV-2 test result (positive or negative).





Abbreviations: VE: vaccine effectiveness;  $V_{cov}$ : probability of receiving recent COVID-19 booster;  $RDT_v$ : probability of home testing among vaccinated;  $RDT_u$ : probability of home testing among unvaccinated;  $HS_v$ : probability of seeking care among vaccinated given no home testing;  $HS_u$ : probability of seeking care among unvaccinated given no home testing;  $HS_vRDT+$ : probability of seeking care among vaccinated given positive test;  $HS_vRDT-$ : probability of seeking care among vaccinated given negative test;  $HS_uRDT+$ : probability of seeking care among unvaccinated given positive test;  $HS_uRDT-$ : probability of seeking care among unvaccinated given negative test.



**Supplemental Table 1:** Beta distribution shape parameters for decision tree factors affecting COVID-19 vaccine effectiveness estimation.

Name	Description	Distribution	Parameter 1: Positive Responses	Parameter 2: Negative Responses	Graph	Minimum	Maximum	Mean	SD	Source
Vaccination <sup>†</sup>										
$V_{cov}$	COVID vaccination uptake	beta	1335	583		0	1	0.70	0.01	Chasing COVID Cohort
$RDT_v$	Probability of home testing among vaccinated	beta	497	838		0	1	0.37	0.01	Chasing COVID Cohort
$RDT_u$	Probability of home testing among unvaccinated	beta	126	457		0	1	0.22	0.02	Chasing COVID Cohort
$HS_vRDT_+$	Probability of seeking care among vaccinated given positive home test	beta	86	98		0	1	0.47	0.04	Chasing COVID Cohort
$HS_vRDT_-$	Probability of seeking care among vaccinated given negative home test	beta	94	219		0	1	0.30	0.03	Chasing COVID Cohort
$HS_v$	Probability of seeking care among vaccinated given no home testing	beta	192	646		0	1	0.23	0.01	Chasing COVID Cohort
$HS_uRDT_+$	Probability of seeking care among	beta	28	35		0	1	0.44	0.06	Chasing COVID Cohort

	unvaccinated given positive home test										
<b><i>HS<sub>u</sub>RDT.</i></b>	Probability of seeking care among unvaccinated given negative home test	beta	15	48		0	1	0.24	0.05	Chasing COVID Cohort	
<b><i>HS<sub>u</sub></i></b>	Probability of seeking care among unvaccinated given no home testing	beta	105	352		0	1	0.23	0.02	Chasing COVID Cohort	

Abbreviations ARI: acute respiratory illness; RDT: rapid diagnostic test; HS: healthcare seeking; SD: standard deviation

Standard deviation for variance of the distribution was calculated using the formula  $\sigma = \mu(1 - \mu) / (T + 1)$ ; where  $\mu$  (mean) =  $\alpha / (\alpha + \beta)$ ;  $T$  (precision) =  $\alpha + \beta$ ; and  $\alpha, \beta$ , denote parameters 1 and 2.

**Supplemental Table 2:** Definition of simulation parameters from CHASING COVID Cohort study surveys

Parameter notation	Description	Definition	Survey Question
N	Survey population	Study population defined reporting ARI symptoms and have completed the prior survey	Since you completed your last survey, have you had any of the following symptoms? [cough, runny nose, sore throat, shortness of breath]
$V_{cov}^{\ddagger}$	COVID-19 vaccination uptake	Vaccination status was defined as receiving the booster at or before prior survey fielding date.	Since your last survey, have you received a COVID-19 booster?
RDT	Home testing	Home testing was defined as receiving an at-home RDT and motivated to test due to ARI symptoms	Since you completed your last survey, were any of your viral tests an at-home rapid test? and If selected yes was tested or tried to get a test, what motivated you to get or try to get a test for COVID-19? Please select all that apply. [I was experiencing COVID-19-like symptoms]
RDT+/- <sup>‡‡</sup>	SARS-CoV-2 viral test result	SARS-CoV-2 test result among at-home RDT users	If took an at-home rapid test: Since you completed your last survey, what was the result of your at-home rapid test(s)? Since you completed your last survey, were any of your viral (PCR or rapid) test(s) positive/reactive?
HS	Healthcare seeking	Healthcare seeking for symptoms	Have you seen or called a physician or health care professional for any of these symptoms?

Abbreviations ARI: acute respiratory illness; RDT: at-home rapid diagnostic test; HS: healthcare seeking

<sup>‡</sup> Vaccination status based on whether respondents reported receiving the most recent booster dose at or before the prior questionnaire's fielding day. For participants who completed the survey questionnaire administered between March and September 2022, vaccination was defined as those who received the second mRNA monovalent COVID-19 booster vaccine (fourth COVID-19 dose). From September 2022 through September 2023, vaccination status was based as those who received the bivalent mRNA COVID-19 vaccine. During October 2023, vaccination was based on those who received the updated 2023-2024 COVID-19 vaccine booster dose.

---

*Unvaccinated participants are those who did not receive the most recent booster dose at or before prior survey's fielding day.*

*# SARS-CoV-2 test result based on at-home RDT use was only ascertained in survey administered in March 2022 (V10); for all other surveys, SARS-CoV-2 viral test result was based on response to any viral test result.*

---

**Supplemental Table 3:** Bias between true VE and  $\widehat{VE}$  based on 10%-point increase or decrease of probability of healthcare seeking among unvaccinated test-negative controls in the base model.

True VE (%)	Probability of healthcare seeking among unvaccinated controls ( $HS_{uRDT-}$ )			
	+ 10%-point $HS_{uRDT-}$	Percent bias <sup>‡</sup>	- 10%-point $HS_{uRDT-}$	Percent bias <sup>‡</sup>
5	-8.7	-13.7	9.9	4.9
10	-3.0	-13.0	14.6	4.6
20	8.5	-11.5	24.1	4.1
40	31.3	-8.7	43.1	3.1
60	54.2	-5.8	62.1	2.1
80	77.1	-2.9	81.0	1.0
95	94.28	-0.7	95.26	0.3

<sup>‡</sup>Percent bias is the absolute difference between observed VE ( $\widehat{VE}$ ) and true VE.

Abbreviations ARI: acute respiratory illness; RDT: rapid diagnostic test; HS: healthcare seeking; VE: vaccine COVID-19 effectiveness

## References:

1. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med*. 2021;27(12):2127-2135.
2. Payne AB, Ciesla AA, Rowley EAK, et al. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. *Vaccine*. Published online November 23, 2023. doi:10.1016/j.vaccine.2023.11.025
3. Dean NE, Hogan JW, Schnitzer ME. Covid-19 vaccine effectiveness and the test-negative design. *N Engl J Med*. 2021;385(15):1431-1433.
4. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*. 2013;31(17):2165-2168.
5. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. *Am J Epidemiol*. 2016;184(5):345-353.
6. Ciocănea-Teodorescu I, Nason M, Sjölander A, Gabriel EE. Adjustment for disease severity in the test-negative study design. *Am J Epidemiol*. 2021;190(9):1882-1889.
7. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. *Vaccine*. 2013;31(30):3104-3109.
8. Goggolidou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T. Self-testing as an invaluable tool in fighting the COVID-19 pandemic. *J Prim Care Community Health*. 2021;12:21501327211047784.
9. Standing Committee for CDC Center for Preparedness and Response, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. *Rapid Expert Consultation on Self-Tests for Infectious Diseases*. National Academies Press; 2022.
10. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(13):489-494.
11. Vose D. *A Guide to Monte Carlo Simulation Modeling*. Wiley; 1996.
12. CHASING COVID cohort study. CUNY ISPH. Accessed March 17, 2024. <https://cunyisph.org/chasing-covid/>
13. Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites - Pima County, Arizona, November 3-17, 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(3):100-105.

14. Wiegand R, Fireman B, Najdowski M, Tenforde M, Link-Gelles R, Ferdinands J. Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection. *Research Square*. Published online August 5, 2024. <https://www.researchsquare.com/article/rs-4802667/v1>
15. Weinstein N, Schwarz K, Chan I, et al. COVID-19 vaccine hesitancy among US adults: Safety and effectiveness perceptions and messaging to increase vaccine confidence and intent to vaccinate. *Public Health Rep*. 2024;139(1):102-111.
16. Nguyen KH, Chung EL, McChesney C, Vasudevan L, Allen JD, Bednarczyk RA. Changes in general and COVID-19 vaccine hesitancy among U.S. adults from 2021 to 2022. *Ann Med*. 2024;56(1):2357230.
17. Dorabawila V, Barnes V, Ramesh N, et al. Comparison of COVID-19 home-testers vs. laboratory-testers in New York State (excluding New York City), November 2021 to April 2022. *Front Public Health*. 2023;11:1058644.
18. Boehmer TK, Koumans EH, Skillen EL, et al. Racial and ethnic disparities in outpatient treatment of COVID-19 - United States, January-July 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(43):1359-1365.
19. Sparling A, Walls M, Mayfield CA, et al. Racial/ethnic disparities in health care setting choice for adults seeking severe acute respiratory syndrome Coronavirus 2 testing. *Med Care*. 2022;60(1):3-12.
20. Priem JS, Krinner LM, Constantine ST, McCurdy L. Diversification of COVID-19 testing resources to decrease racial/ethnic disparities: Comparative use of adaptive approaches to community testing across an integrated healthcare system. *Dialogues Health*. 2022;1(100017):100017.
21. Zhou RA, Baicker K, Taubman S, Finkelstein AN. The uninsured do not use the emergency department more-they use other care less. *Health Aff (Millwood)*. 2017;36(12):2115-2122.
22. Bodner K, Irvine MA, Kwong JC, Mishra S. Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies. *Int J Infect Dis*. 2023;131:111-114.
23. Qasmieh SA, Robertson MM, Rane MS, et al. The importance of incorporating at-home testing into SARS-CoV-2 point prevalence estimates: Findings from a US national cohort, February 2022. *JMIR Public Health Surveill*. 2022;8(12):e38196.
24. Qasmieh SA, Robertson MM, Teasdale CA, et al. The prevalence of SARS-CoV-2 infection and other public health outcomes during the BA.2/BA.2.12.1 surge, New York City, April-May 2022. *Commun Med (Lond)*. 2023;3(1):92.

25. Qasmieh SA, Robertson MM, Teasdale CA, et al. The prevalence of SARS-CoV-2 infection and long COVID in U.S. adults during the BA.4/BA.5 surge, June-July 2022. *Prev Med.* 2023;169(107461):107461.
26. Assistant Secretary for Public Affairs (ASPA). Biden-Harris Administration requires insurance companies and group health plans to cover the cost of at-home COVID-19 tests, increasing access to free tests. US Department of Health and Human Services. January 10, 2022. Accessed April 2, 2023. <https://www.hhs.gov/about/news/2022/01/10/biden-harris-administration-requires-insurance-companies-group-health-plans-to-cover-cost-at-home-covid-19-tests-increasing-access-free-tests.html>
27. The White House. Fact sheet: The Biden Administration to begin distributing at-home, rapid COVID-19 tests to Americans for Free. The White House. January 14, 2022. Accessed April 2, 2023. <https://www.whitehouse.gov/briefing-room/statements-releases/2022/01/14/fact-sheet-the-biden-administration-to-begin-distributing-at-home-rapid-covid-19-tests-to-americans-for-free/>
28. Qasmieh, S., Robertson, M. & Nash, D. “Boosting” surveillance for a more impactful public health response during protracted and evolving infection disease threats: insights from the COVID-19 pandemic. Health Security (in press). *Health Secu.*
29. Luisi N, Sullivan PS, Sanchez T, et al. Use of Covidtests.gov at-home test kits among adults in a national household probability sample - United States, 2022. *MMWR Morb Mortal Wkly Rep.* 2023;72(16):445-449.
30. Ritchey MD, Rosenblum HG, Del Guercio K, et al. COVID-19 Self-Test Data: Challenges and Opportunities — United States, October 31, 2021–June 11, 2022. *MMWR Morbidity and Mortality Weekly Report.* 2022;71(32):1005-1010. doi:10.15585/mmwr.mm7132a1